financetom
Business
financetom
/
Business
/
Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies
Jun 17, 2024 8:14 AM

Monday, Mirum Pharmaceuticals Inc. ( MIRM )  announced interim results from two Phase 2b studies evaluating volixibat for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).

Interim results from the VANTAGE study evaluating volixibat in patients with PBC demonstrated a statistically significant (-3.82, p

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Carlyle-backed Crescent Midstream to build carbon capture and storage unit in Louisiana
Carlyle-backed Crescent Midstream to build carbon capture and storage unit in Louisiana
Oct 3, 2024
Sept 20 (Reuters) - Oil pipeline firm Crescent Midstream, which is backed by investment firm Carlyle Group ( CG ), said on Friday it would jointly develop and construct a carbon capture and storage project in Lake Charles, Louisiana. The nearly $1 billion project would capture carbon dioxide from an Entergy ( ETR )-owned natural gas-fired power plant, the 994...
Market Chatter: B. Riley Financial in Discussions to Sell Wealth Management Business to Stifel Financial
Market Chatter: B. Riley Financial in Discussions to Sell Wealth Management Business to Stifel Financial
Oct 3, 2024
02:49 PM EDT, 09/20/2024 (MT Newswires) -- B. Riley Financial ( RILY ) is in discussions with Stifel Financial ( SF ) for the sale of its wealth management business for over $100 million, Reuters reported Friday, citing a source familiar with the matter. There is no guarantee the talks will result in a sale, the source reportedly said. Stifel...
Gilead Sciences Unusual Options Activity For September 20
Gilead Sciences Unusual Options Activity For September 20
Oct 3, 2024
High-rolling investors have positioned themselves bearish on Gilead Sciences ( GILD ) , and it's important for retail traders to take note. This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in GILD often signals that someone has privileged information. Today, Benzinga's...
Exclusive-Financial software maker Enfusion explores options including sale, sources say
Exclusive-Financial software maker Enfusion explores options including sale, sources say
Oct 3, 2024
NEW YORK (Reuters) -Enfusion, a U.S. software provider for asset managers, is in talks with investment bankers to evaluate options that could include a potential sale, according to people familiar with the matter. The Chicago-based company, which has a market value of $1.1 billion, decided to interview investment banks in recent weeks after receiving takeover interest from potential suitors including...
Copyright 2023-2026 - www.financetom.com All Rights Reserved